TY - JOUR ID - 10442/17640 A1 - Chantzi N.I. A1 - A1 - Tiniakos D.G. A1 - A1 - Palaiologou M. A1 - A1 - Goutas N. A1 - A1 - Filippidis T. A1 - A1 - Vassilaros S.D. A1 - A1 - Dhimolea E. A1 - A1 - Mitsiou D.J. A1 - A1 - Alexis M.N. Y1 - 2013/// T1 - Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma JF - Journal of Cancer Research and Clinical Oncology VL - 139 IS - 9 SN - 0171-5216 U3 - 10.1007/s00432-013-1467-4 SP - 1489–1498EP - UR - https://hdl.handle.net/10442/17640 N2 - Our aim was to examine the prognostic significance of ERbeta1 and ERbeta2 expression in ERalpha-negative breast carcinomas. Materials and methods: We evaluated nuclear and cytoplasmic expression of ERbeta1 and ERbeta2 by immunohistochemistry in a group of 95 patients with long follow-up. ERbeta1 and ERbeta2 status was correlated with clinicopathological parameters and disease outcome. Univariate and multivariate analyses of ERbeta1 and ERbeta2 as independent markers of disease-free survival (DFS) were carried out using the Cox proportional hazards model. Results: Nuclear ERbeta1 (nERbeta1) and nERbeta2 status was positively correlated (p = 0.01). nERbeta1 positivity was associated with low histological grade (p = 0.01) in all patients and in the nERbeta2-positive subgroup (p = 0.03) but not in the nERbeta2-negative (p = 0.27). nERbeta2 positivity was associated with lymph node involvement and tumor relapse in all cases (p < 0.00 and p < 0.00, respectively) and in the nERbeta1-negative subgroup (p < 0.00 and p < 0.00, respectively) but not in the nERbeta1-positive (p = 0.09 and p = 0.20, respectively). nERbeta2 positivity was associated with poor DFS in all patients (log-rank p <0.00), in the post-menopausal patient subgroup (log-rank p = 0.02) and in the HER2-negative (triple-negative) subgroup (log-rank p = 0.04). Cox multivariate analysis including ERbeta1, ERbeta2 and established clinicopathological variables highlighted ERbeta2 as an independent marker of early disease recurrence (hazard ratio 4.87; 95 % confidence interval 1.07-22.3; p = 0.04). Conclusion: High nERbeta2 is an independent marker of early relapse in ERalpha-negative breast carcinoma, and in particular, in the nERbeta1-negative, the post-menopausal patient and the triple-negative subgroups. These findings suggest that inhibition of expression and/or function of ERbeta2 could improve disease outcome. ER -